On November 6, Pfizer announced that the new indications for the world's first non-factorial innovative drug, Youruinine®, which only requires a fixed dose subcutaneous injection once a week, have been officially approved by the China National Drug Administration for routine preventive treatment of children and adults aged 12 and above with type A hemophilia with coagulation factor VIII inhibitors or type B hemophilia with coagulation factor IX inhibitors and adults weighing at least 35 kg to prevent bleeding or reduce the frequency of bleeding episodes.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.